JP7273030B6 - シクロオレフィン置換複素芳香族化合物およびそれらの使用 - Google Patents

シクロオレフィン置換複素芳香族化合物およびそれらの使用 Download PDF

Info

Publication number
JP7273030B6
JP7273030B6 JP2020513872A JP2020513872A JP7273030B6 JP 7273030 B6 JP7273030 B6 JP 7273030B6 JP 2020513872 A JP2020513872 A JP 2020513872A JP 2020513872 A JP2020513872 A JP 2020513872A JP 7273030 B6 JP7273030 B6 JP 7273030B6
Authority
JP
Japan
Prior art keywords
formula
compound
alkyl
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020513872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533319A (ja
JP7273030B2 (ja
JP2020533319A5 (https=
Inventor
ス、ウェイ－グオ
ダイ、グワンシュ
シャオ、クン
Original Assignee
ハチソン メディファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハチソン メディファーマ リミテッド filed Critical ハチソン メディファーマ リミテッド
Publication of JP2020533319A publication Critical patent/JP2020533319A/ja
Publication of JP2020533319A5 publication Critical patent/JP2020533319A5/ja
Priority to JP2023072737A priority Critical patent/JP7603740B2/ja
Application granted granted Critical
Publication of JP7273030B2 publication Critical patent/JP7273030B2/ja
Publication of JP7273030B6 publication Critical patent/JP7273030B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2020513872A 2017-09-07 2018-09-07 シクロオレフィン置換複素芳香族化合物およびそれらの使用 Active JP7273030B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023072737A JP7603740B2 (ja) 2017-09-07 2023-04-26 シクロオレフィン置換複素芳香族化合物およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710801364.3 2017-09-07
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072737A Division JP7603740B2 (ja) 2017-09-07 2023-04-26 シクロオレフィン置換複素芳香族化合物およびそれらの使用

Publications (4)

Publication Number Publication Date
JP2020533319A JP2020533319A (ja) 2020-11-19
JP2020533319A5 JP2020533319A5 (https=) 2021-10-14
JP7273030B2 JP7273030B2 (ja) 2023-05-12
JP7273030B6 true JP7273030B6 (ja) 2024-02-15

Family

ID=65634832

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513872A Active JP7273030B6 (ja) 2017-09-07 2018-09-07 シクロオレフィン置換複素芳香族化合物およびそれらの使用
JP2023072737A Active JP7603740B2 (ja) 2017-09-07 2023-04-26 シクロオレフィン置換複素芳香族化合物およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023072737A Active JP7603740B2 (ja) 2017-09-07 2023-04-26 シクロオレフィン置換複素芳香族化合物およびそれらの使用

Country Status (19)

Country Link
US (3) US11414390B2 (https=)
EP (1) EP3679020A4 (https=)
JP (2) JP7273030B6 (https=)
KR (1) KR102566237B1 (https=)
CN (6) CN109467538A (https=)
AR (1) AR112794A1 (https=)
AU (1) AU2018329047B2 (https=)
CA (1) CA3073782A1 (https=)
CL (1) CL2020000553A1 (https=)
EA (1) EA202090653A1 (https=)
IL (1) IL272923B2 (https=)
MX (1) MX2020002505A (https=)
PE (1) PE20200727A1 (https=)
PH (1) PH12020500408A1 (https=)
SG (1) SG11202001642WA (https=)
TW (1) TWI816693B (https=)
UA (1) UA129118C2 (https=)
WO (1) WO2019047909A1 (https=)
ZA (1) ZA202001448B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
CN116209655A (zh) * 2020-11-09 2023-06-02 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (zh) * 2022-01-11 2023-07-20 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008122378A1 (en) 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JP2009536615A (ja) 2006-04-07 2009-10-15 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
JP2011501752A (ja) 2007-10-17 2011-01-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
WO2012003283A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
CN103044469A (zh) 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
JP2014527082A (ja) 2011-09-12 2014-10-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
JP2016502511A (ja) 2012-10-24 2016-01-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性アジン
JP2016523935A (ja) 2013-07-11 2016-08-12 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法
JP2016526561A (ja) 2013-07-11 2016-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびそれらの使用方法
JP2016540728A (ja) 2013-11-01 2016-12-28 ノバルティス アーゲー キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
WO2017016513A1 (zh) 2015-07-30 2017-02-02 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物及其使用方法
WO2017096945A1 (zh) 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
JP2017516826A (ja) 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AU2005247441A1 (en) 2004-05-24 2005-12-08 Equusys, Incorporated Animal instrumentation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2008031556A2 (en) * 2006-09-12 2008-03-20 Ucb Pharma, S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
US9862692B2 (en) 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
MY185687A (en) * 2013-07-11 2021-05-30 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
TWI666208B (zh) 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 治療活性化合物及其使用方法（三）
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
HUE064145T2 (hu) 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
JP6557441B1 (ja) 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536615A (ja) 2006-04-07 2009-10-15 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2008122378A1 (en) 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JP2011501752A (ja) 2007-10-17 2011-01-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
WO2012003283A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
JP2014527082A (ja) 2011-09-12 2014-10-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ活性のモジュレーターとして使用するためのアミノピリミジン誘導体
JP2016502511A (ja) 2012-10-24 2016-01-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性アジン
CN103044469A (zh) 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
JP2016523935A (ja) 2013-07-11 2016-08-12 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびその使用方法
JP2016526561A (ja) 2013-07-11 2016-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物およびそれらの使用方法
JP2016540728A (ja) 2013-11-01 2016-12-28 ノバルティス アーゲー キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
JP2017516826A (ja) 2014-06-04 2017-06-22 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
WO2017016513A1 (zh) 2015-07-30 2017-02-02 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物及其使用方法
WO2017096945A1 (zh) 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Baird, Mark S.，A simple route to 3-(dihalomethylene)cycloalkenes，Tetrahedron Letters，1982年，23(37),，3795-6
Bessiere-Chretien, Y.，Ene syntheses in the s-triazine series，Journal of Heterocyclic Chemistry ，1974年，11(3),，317-19
Garcia Martinez, Antonio，Fragmentation of vinyl triflates by electron impact. Mechanism of an unusual double hydrogen atom transfer reaction，Rapid Communications in Mass Spectrometry，1994年，8(5),，427-31
REGISTRY(STN)[online]，2016年，[検索日 2022.05.26] CAS登録番号 1993034-73-3、1622560-40-0

Also Published As

Publication number Publication date
BR112020004563A2 (pt) 2020-09-08
CN111132967B (zh) 2023-08-04
TW201912632A (zh) 2019-04-01
AU2018329047A1 (en) 2020-03-12
US20210363115A2 (en) 2021-11-25
JP7603740B2 (ja) 2024-12-20
CN117257809A (zh) 2023-12-22
PE20200727A1 (es) 2020-07-23
CL2020000553A1 (es) 2020-08-07
CN111132967A (zh) 2020-05-08
CN116999441A (zh) 2023-11-07
EP3679020A4 (en) 2021-05-05
UA129118C2 (uk) 2025-01-22
JP2020533319A (ja) 2020-11-19
US20250223267A1 (en) 2025-07-10
CN109467538A (zh) 2019-03-15
JP7273030B2 (ja) 2023-05-12
US11414390B2 (en) 2022-08-16
SG11202001642WA (en) 2020-03-30
EA202090653A1 (ru) 2021-02-03
KR102566237B1 (ko) 2023-08-14
PH12020500408A1 (en) 2021-03-01
CN117024363A (zh) 2023-11-10
AU2018329047B2 (en) 2023-09-07
US12234211B2 (en) 2025-02-25
IL272923A (en) 2020-04-30
TWI816693B (zh) 2023-10-01
IL272923B2 (en) 2023-06-01
CA3073782A1 (en) 2019-03-14
AR112794A1 (es) 2019-12-11
ZA202001448B (en) 2024-11-27
CN117797156A (zh) 2024-04-02
NZ762447A (en) 2023-09-29
JP2023103290A (ja) 2023-07-26
MX2020002505A (es) 2020-07-20
US20210163426A1 (en) 2021-06-03
EP3679020A1 (en) 2020-07-15
US20220372005A1 (en) 2022-11-24
WO2019047909A1 (en) 2019-03-14
KR20200052321A (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
JP7603740B2 (ja) シクロオレフィン置換複素芳香族化合物およびそれらの使用
JP2017031207A (ja) 置換６，６−縮合窒素複素環化合物及びその使用
TW202140488A (zh) 雜芳基雜環化合物及其用途
JP2022550353A (ja) アザキノリン化合物およびその使用
KR20230167347A (ko) 트리사이클릭 화합물 및 이의 용도
JP2023542040A (ja) ヘテロアリール複素環化合物及びその使用
WO2020228823A1 (en) Novel amide compounds and uses thereof
CN112047877A (zh) 新型酰胺类化合物及其用途
HK40097382A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40098874A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40096142A (zh) 环烯烃取代的杂芳环类化合物及其用途
HK40109090A (zh) 环烯烃取代的杂芳环类化合物及其用途
BR112020004563B1 (pt) Compostos heteroaromáticos substituídos por ciclo-olefina e seu uso
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use
NZ762447B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
HK40027076B (zh) 环烯烃取代的杂芳环类化合物及其用途
EA044101B1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
JP2025530791A (ja) トリアジン化合物及びその使用
WO2021136464A1 (en) Novel amide compounds and uses thereof
TW202220988A (zh) 雜芳環類化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230427

R150 Certificate of patent or registration of utility model

Ref document number: 7273030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150